Search results for: 'cmo ad pfa clinical'

08 Nov 2024  |  Global  |  Market Research

Analysis of the Clinical Next-generation Sequencing Sector, Global, 2024-2030

Continued Investment in AI is Driving Transformational Growth by Accelerating Information Solutions Development

Infographics

×

This Frost & Sullivan analysis examines the clinical next-generation sequencing (NGS) industry, covering the different type of products, workflows, and applications for clinical purposes. The global market is projected to grow steadily from 2024 to 2030, achieving significant revenue milestones, driven largely by services and informatics segments. ...

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and translation of blood-based neurology biomarkers, sustai...

Clinical decision support (CDS) is a broad concept with many definitions that are used variably, depending on the perspective and role of the expert. It includes a mix of evidence (content), analytics, workflow, devices, and software-based solutions that must include electronic health records (EHRs) and be maintained by an IT platform. This repo...

This Frost Radar™ benchmarks the growth and innovation activity of clinical decision support system (CDSS) vendors in their effort to provide end users with evidence to take the next best action. The CDSS role is evolving from just being the source of clinical knowledge at the point of care or facilitating clinical decision-making and workflow. New...

This Frost Radar™ analyzes the clinical ambient AI solutions that enable clinicians to improve their efficiency at the point of care. AI scribe capability has become the baseline market requirement, eliminating it as a differentiator and pushing vendors to compete on higher-order clinical and financial workflow integration. These capabilities inclu...

The Sensor Technology Opportunity Engine provides profiles of innovations related to QD Based Image Sensor For Enhanced Wide Spectrum Imaging, High-Performance, Space-Optimized CMOS Image Sensors for Next-Gen Space Missions, Advanced Human Recognition Sensor for Embedded and Automation Systems and Dual-Sensor System-in-Package for Accurate Motion a...

Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

This market insight covers the challenges associated with the adoption of next-generation sequencing (NGS)-based testing for routine diagnostic use. Emerging applications for gene panel and whole exome sequencing are discussed. Best practices and guidance have been provided to attain coverage on newly launched tests through case study analysis. Tab...

Despite the term patient centricity gaining currency in the industry, there is a degree of variability in a companies’ approach and strategic priorities. Frost & Sullivan sees digitization playing a critical role in transforming the clinical trial model from traditional, high-cost, and difficult-to-access centralized settings to more patient-centri...